

The Heart of Anti-Aging


Giovanni Campanile, MD, FACC, FAARM Scott Berliner, R.Ph.



Life expectancy in 1800, 1950, and 2015 Our World in Data Life expectancy in 1800 in the borders of 2015 Americas: 35 years Africa: 26 years Historical estimates suggest that up to at least the year 1800 the life expectancy for people in all countries |Global average: ~29 years 25 years 40 years 50 years 60 years 70 years 80 years 85 years was less than 40 years. These historical estimates come with substantial uncertainty. Life expectancy in 1950 in the borders of 2015 68 years Europe: 62 years Northern America: 68 years South America: 51 years Oceania: 61 years Global average: 46 years 25 years 40 years 50 years 60 years 70 years 80 years 85 years Life expectancy in 2015 Northern America: 80 years 7.75 South America: 75 years Data: Our World in Data based on Riley (2006) for regional and global averages in 1800. Gapminder for country estimates in 1800. United Nations Population Division for country estimates in 1950 and 2015 |Global average: 71 years | 70 years 80 years 85 years 25 years 40 years 50 years 60 years Licensed under CC-BY-SA by the author Max Ro

Life Expectancy at Birth

Reversal of Established Disease




Source: Encyclopedia Britannica, Census Bureau, 2010

This deal got us age-related diseases, their accumulation and bad quality of life

Causes of death, World, 2019




The estimated annual number of deaths from each cause. Estimates come with wide uncertainties, especially for countries with poor vital registration¹.




1. Civil and Vital Registration System: A Civil and Vital Registration System (CVRS) is an administrative system in a country that manages information on births, marriages, deaths and divorces. It generates and stores 'vital records' and legal documents such as birth certificates and death certificates.
You can read more about how deaths are registered around the world in our article: How are causes of death registered around the world?

Nontraditional CVD Risk Factors




Causes of elevated Apo B Chol Synthesis, Reabsorption, Clearance (LDLr) Triglyceride Burden / Insulin Resistance



4 Big Risk Factors for CAD:
Apo B
Insulin Resistance
HTN
Smoking


All Data link ApoB with ASCVD:
Epidemiological
Clinical Trials
Mendelian
Randomizatio

JAMA Cardiol. 2019 Dec 1;4(12):1287-1295. doi: 10.1001/jamacardio.2019.3780





Gissette Reyes-Soffer. Arteriosclerosis, Thrombosis, and Vascular Biology. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association, Volume: 42, Issue: 1, Pages: e48-e60, DOI: (10.1161/ATV.00000000000000147)




T1 - Hyperglycemia and Endothelial Dysfunction in Atherosclerosis: Lessons from Type 1 Diabetes 10.1155/2012/569654 International journal of vascular medicine

"Atherosclerosis is a multifocal, smoldering, immunoinflammatory disease of medium-sized and large arteries fuelled by lipids." [Falk, 2006]

First Sign of a MI - Sudden Death 50% in men 69% in women



Myocardial Infarction: Histopathology and Timing of Changes https://doi.org/10.1177/2374289520976639





Nitric Oxide Supplements

Arginine may not be the best option anymore. Research may not have caught up though


Other options:

L-Citrulline
Potassium Nitrate
Beet Root Powder





Park HY, Kim SW, Seo J, Jung YP, Kim H, Kim AJ, Kim S, Lim K. Dietary Arginine and Citrulline Supplements for Cardiovascular Health and Athletic Performance: A Narrative Review. Nutrients. 2023 Mar 3;15(5):1268. doi: 10.3390/nu15051268. PMID: 36904267; PMCID: PMC10005484.




Gut microbiota-dependent metabolite trimethylamine Noxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

Clin Res Cardiol. 2022; 111(6): 692-704




Mechanosensing and mechanotransduction



Flow-induced vasodilatation reactive hyperhemia


Flow-induced NO production

Space between blood and vessel wall



Prevention of leukocytes adhesion and extravasation


Selective permeability barrier



Protection Protection against against proteinuria tissue edema

Restriction of high molecular weight Dextran acces





Direct effect of shear stress on plasma membrane




Sophie Dogné. Arteriosclerosis, Thrombosis, and Vascular Biology. Endothelial Glycocalyx as a Shield Against Diabetic Vascular Complications, Volume: 38, Issue: 7, Pages: 1427-1439, DOI: (10.1161/ATVBAHA.118.310839)

Glycocheck


A side-stream dark field camera visualizes passing red blood cells (RBC) by emitting stroboscopic green light in the sublingual microcirculation.

The dedicated Glycocheck™ software then estimates the dynamic lateral RBC movement into the glycocalyx, which is expressed as the perfused boundary region (PBR; in µm)




Chondroitin Sulfate Glucosamine Sulfate

Treatment	Reference
Hydrocortisone	Chappell et al. 2007, 2009b, 2010 [41, 43, 44]
Antithrombin	Chappell et al. 2009a, 2009b, 2010 [42–44]
Protein C	Marechal et al. 2008 [50]
Nitric oxide	Bruegger et al. 2008 [45]
Hyaluronic acid and chondroitin sulphate	Henry and Duling 1999 [13]
Sulodexide	Broekhuizen et al. 2010 [54]
Lidoflazine	Flameng et al. 1983 [55]
Albumin	Jacob et al. 2006, 2009 [46, 47]
Hydroxethyl starch	Rehm et al. 2004; Jacob et al. 2006 [8, 46]
N-acetylcysteine	Nieuwdorp et al. 2006 [9]
Metformin	Eskens et al. 2013 [51]






Rhamnan Sulfate








SCIENCE ADVANCES 16 Jul 2021 Vol 7, Issue 29

Helen Hobbs in early 2000's discovered a group with a mutation in PCSK9 Gene less PCSK9 - less degradation of LDLR LDLc-10-20mg/dl, no CAD No increase of other diseases - Cancer, DM2, Dementia


Another group hyperfunctioning gene reduced LDLR, increased
LDLc & CAD - form of FH

How does PCSK9 work?




a) Secreted PCSK9 binds to LDLR on the liver cell surface and mediates the lysosomal degradation of the complex formed by PCSK9 - LDLR - LDL.

How does Inhibitors work?



b) In the presence of a monoclonal antibody that binds to PCSK9, the PCSK9-mediated degradation of LDLR is inhibited, resulting in an increased uptake of LDL-cholesterol by LDLR as more LDLR are recycled at the cell surface.





Reindert F. Oostveen. Arteriosclerosis, Thrombosis, and Vascular Biology. New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing, Volume: 43, Issue: 7, Pages: 1081-1092, DOI: (10.1161/ATVBAHA.122.317963)

Statins - 7% Muscle aches
Increase in Transaminases
Ins resistance - 0.4% DM2
Follow HgbA1C, Insulin,
CGM

No convincing data on negative Mitochondrial effects Zone 2 testing (180-age) No good data that CoQ10 helps

Cholesterol Pool Sizes

9.36 gms = 0.33 oz = ~ 2 tsp	mg/kg	g/70 kg
Liver	27.0	1.89
Red blood cells	37.0	2.59
Lipoproteins	20.3	1.42
Peripheral tissues	133.7	9.36

Investigators concluded that neither the size nor turnover of these pools was significantly affected by blood lipid or lipoprotein levels nor by statin treatment, and thus whole-body cholesterol turnover did not correlate with the usual parameters of atherosclerotic risk

Cholesterol is essential for Life Smith-Lemli -Optz Syndrome: Microencephaly, death

Statin Pleiotropy

Increased synthesis of nitric oxide Improvement of endothelial dysfunction Inhibition of free radical release Decreased synthesis of endothelin-1 Inhibition of LDL-C oxidation Upregulation of endothelial progenitor cells Reduced number and activity of inflammatory cells Reduced inflammatory response Reduced levels of C-reactive protein Reduced macrophage cholesterol accumulation Stabilization of atherosclerotic plaques Reduced production of metalloproteinases Inhibition of platelet adhesion/aggregation Reduced thrombogenic response Reduced fibrinogen concentration Reduced blood viscosity



Red yeast rice preparations have been shown to be safe and effective in improving lipid profiles, and, to some extent in reducing the risk of cardiovascular events. Red yeast rice should not routinely be used in the place of conventional treatments (statins, ezetimibe and PCSK9 inhibitors) for which higher-quality long-term outcomes data exist. However, in specific situations (statin intolerance, patients with dyslipidaemia ineligible for statin therapy, strong patient preference), the use of red yeast rice may be considered. When recommending a redyeast rice product to patients, it is important to ensure that the product has been produced according to the principles of GMP, to ensure consistency of dose of the active ingredient, and the absence of harmful contaminants

Banach M, Catapano AL, Cicero AFG, Escobar C, Foger B, Katsiki N, Latkovskis G, Rakowski M, Reiner Z, Sahebkar A, Sikand G, Penson PE, On Behalf Of The International Lipid Expert Panel Ilep. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel. Pharmacol Res. 2022 Sep;183:106370. doi: 10.1016/j.phrs.2022.106370. Epub 2022 Jul 25. PMID: 35901940.

Some red yeast rice products contain a contaminant called citrinin, which is toxic and can damage the kidneys.

In a 2021 analysis of 37 red yeast rice products, only one had citrinin levels below the maximum level currently set by the European Union.

Red Yeast Rice for Hyperlipidemia

RYR at 200–4800 mg daily appears to be a safe and effective treatment for hyperlipidemia, effectively regulating blood lipid levels with an exceptional impact on TG.

Looking forward, high-quality clinical trials with longer observation periods are required to evaluate the efficacy and safety of RYR as a long-term medication.

 RYR should be considered for patients who have a suboptimal lipid profile despite diet and lifestyle interventions (IIaB)

Patients not indicated for statin therapy owing to low CVD risk

 In primary prevention, in pts who are unwilling to take a statin, RYR is recommended alone or in combination with other available LLTs (IC)

Patients who are unwilling to take statin/any lipid lowering drug

Patients with statin intolerance and the drucebo effect

Patients with statin intolerance and the drucebo effect

 RYR may be considered as part of a supportive strategy to manage dyslipidaemias and CV risk in SAMS likely to result from the drucebo effect (IIbC) RYR should be considered as an alternative approach to statins in patients with confirmed statin intolerance (IIaB)


CoQ10 Ubiquinone & Ubiquinol

Ubiquinone

coenzyme Q10, or CoQ10

Patients with heart failure with preserved ejection fraction (HFpEF) have few pharmacologic therapies, and it is not known if supplementing with ubiquinol and/or d-ribose could improve outcomes. The overall objective of this study was to determine if ubiquinol and/or d-ribose would reduce the symptoms and improve cardiac performance in patients with HFpEF.

In conclusion, ubiquinol and d-ribose reduced the symptoms of HFpEF and increased the EF. These findings support the use of these supplements in addition to standard therapeutic treatments for patients with HFpEF.



coenzyme Q10, or QH

Pierce JD, Shen Q, Mahoney DE, Rahman F, Krueger KJ, Diaz FJ, Clark L, Smith C, Vacek J, Hiebert JB. Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol. 2022 Aug 1;176:79-88. doi: 10.1016/j.amjcard.2022.04.031. Epub 2022 May 27. PMID: 35644694; PMCID: PMC9576187.

Test Name	08/04/2023	01/06/2023	06/16/2022	06/15/2022	03/30/2022	02/01/2022
	(Current)					
LIPID PANEL		105			1.40	
TRIGLYCERIDES	115	105	100	-	148	284
CHOLESTEROL, TOTAL	152	152	122	-	183	192
HDL CHOLESTEROL	50	57	51	-	50	43
LDL-CHOLESTEROL	81	76	53	-	107	108
CHOL/HDLC RATIO	3.0	2.7	2.4	-	3.7	4.5
NON-HDL CHOLESTEROL	102	95	71	-	133	149
LIPOPROTEIN FRACTIONATION, ION	и мо					
LDL PARTICLE NUMBER	1489	1196	826	-	1926	1528
LDL SMALL	368	257	177	-	464	350
LDL MEDIUM	297	214	171	-	447	239
HDL LARGE	5757	7190	4354	-	6958	5259
APOLIPOPROTEINS						
LIPOPROTEIN (a)	66	91	72	-	74	22
APOLIPOPROTEIN A1	-	-	163	-	-	-
APOLIPOPROTEIN B	88	75	62	-	105	109
INFLAMMATION						
HS CRP	0.7	2.5	3.0	-	3.0	1.3
FIBRINOGEN ANTIGEN	-	-	285	-	-	-
SDMA (Symmetric dimethylarginine)	109	108	-	98	-	-
LP PLA2 ACTIVITY	89	80	71	-	92	105

CLIENT SERVICES: 866.697.8





Bergamot




In the present study, we investigated bergamot fruit extract (BFE) and its principal components (neoeriocitrin, naringin, neohesperidin, melitidin, and brutieridin) for their ability to regulate cholesterol levels in HepG2 and Caco-2 cells.

An increase in AMP-kinase phosphorylation was observed in BFE and neohesperidin-treated cells. In Caco-2 cells, brutieridin exhibited a significant reduction in cholesterol uptake and decreased the level of Niemann-Pick C1 Like 1, an important cholesterol transporter. Taken together, our data suggest that the cholesterol-lowering activity of bergamot is distinct from statins. We hypothesize that BFE and its principal constituents lower cholesterol by inhibiting cholesterol synthesis and absorption.






In the United States, between 10,000 and 50,000 heart attacks are missed per year at emergency departments (EDs).



BMJ Quality & Safety, 22 Jan 2018, 27(7):557-566

Front Cardiovasc Med. 2022; 9: 754909.

Electrocardiogram-Based Heart Age Estimation by a Deep Learning Model Provides More Information on the Incidence of Cardiovascular Disorders



From: Deep Learning of Electrocardiograms in Sinus Rhythm From US Veterans to Predict Atrial Fibrillation

JAMA Cardiol. 2023;8(12):1131-1139. doi:10.1001/jamacardio.2023.3701




Figure Legend:

Deep Learning Model Performance Compared With Clinical Risk Factor ModelsPerformance of deep learning model on all electrocardiograms held out from the model training compared with predicting atrial fibrillation using a clinical risk factors model (age; sex; history of heart failure; diabetes; cerebrovascular accident, transient ischemic attack, or thromboembolism; prior myocardial infarction; peripheral vascular disease; and chronic kidney disease) or the CHA₂DS₂-VASc (congestive heart failure, hypertension, age, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age, sex category) score: AUROC indicates area under the receiver operating characteristic curve.


Advanced Lipid Panel

-	
u	5 6

Lipia iooto				
Total Cholesterol			264	
	<200	200-240	>240 mg/dL	
Direct LDL-C			177	
	<100	100-160	>160 mg/dL	
HDL-C		42		
	>50	40-50	<40 mg/dL	
Triglycerides		155		
	<150	150-200	>200 mg/dL	
Non-HDL-C			222	
	<130	130-190	>190 mg/dL	
ApoB			148	
	<80	80-120	>120 mg/dL	
sdLDL-C			46	
	<20	20-40	>40 mg/dL	
%sdLDL-C		26		
	<20	20-30	>30 %	
VLDL-C			45	
	<30	30-40	>40 mg/dL	
Lp(a)	<15			
	<30	30-50	>50 mg/dL	
ApoA-I		145.7		
	>160	120-160	<120 mg/dL	

Lipid Ratios

Lipia Hatioo				
TC/HDL-C			6.3	
	<4	4-6	>6	
VLDL-C/TG		0.29		
	<0.2	0.2-0.3	>0.3	
ApoB/ApoA-I			1.02	
	<0.6	0.6-0.9	>0.9	
HDL-C/TG		0.27		
	>0.5	0.25-0.5	< 0.25	




Clinical Therapeutics/Volume 44, Number 8, 2022
Original Research
Apolipoprotein B Displays Superior Predictive Value
Than Other Lipids for Long-Term Prognosis in
Coronary Atherosclerosis Patients

Cholesterol Balance Laboratory Report: High Cholesterol Absorption

Increased Phytosterols may indicate defective ATP Binding cassette or increased NP receptors Phytosterol Supplements may not be a good idea

OBOSTON Heart Cholesterol Balance® Test1




Interpretation: Increased amounts of Beta-sitosterol and Campesterol may indicate an increase in intestinal absorption of cholesterol. Beta-sitosterol level is very HIGH and consistent with markedly increased cholesterol absorption and may be associated with elevated LDL-C levels, tendon xanthomas, phytosterolemia, and increased heart disease risk.

Consideration: Consider lifestyle modification and ezetimibe therapy.

Cholesterol Balance Laboratory Report: High Cholesterol Production

Desmosterol - Brain Cholesterol (esp in APOE4) Lathosterol - Peripheral Chol Syn



Interpretation: Elevated levels of Lathosterol and Desmosterol may indicate an increased cellular production of cholesterol. Cholesterol Balance Score is very HIGH and consistent with markedly increased cholesterol production.


0.2

0.5

Consideration: Consider lifestyle modification and statin therapy.


Polygenic Risk Map

CAD RISK REPORT



40 45 50 55 60 65 70 75 80 Age


CAD POLYGENIC RISK REPORT



POLYGENIC RISK SCORE EXPLAINED


A polygenic risk score (PRS) measures the component of disease risk from many genetic variants spread throughout the genome. Lifetime risk of CAD is calculated by comparing the tested individual's PRS to a reference population. PRS above the percentile is considered high because it confers a greater than 22% lifetime risk, which is three times the risk of disease compared to the remainder of the population. The chart shows how PRS translates to lifetime risk of coronary artery disease. This CAD PRS comprises 1,926,521 genome-wide variants.

Boston Heart HDL Map $^{\circ}$: "For every 1 mg/dL increase in apoA-I in very large α -1 HDL there is a 26% reduction in CVD risk." 1




APO B - Biomarker & Causally related to ASCVD


May go back to a time when we energy deprived good for us until 100 years ago



We do not really need any Apo B most animals do not have it. Children have ApoB < 20mg/dl Peter Libby B&WH If ApoB <30 - no CAD



In a study of 528 patients with high risk for CV events over 5 years, the EndoPAT reactive hyperemia index (RHI) was measured before and after coronary angiogram.4 The RHI, brain natriuretic peptide (BNP), and CV score by SYNTAX were independent risk predictors for all future CV events such as MI, CV death, unstable angina, ischemic CVA, coronary artery bypass graft, CHF, and PAD. When RHI was added to FRS, BNP, and SYNTAX, the net reclassification index was significantly improved by 27.5 %





DOB

Age 57

Gender Female

Date of scan Report Aug 2022 99

Referring Physician

Sonographer Admin

Page

1/3

Visualized plaque and atherosclerotic burden assessment

65

Vascular Age

Vascular age is a measurement of the apparent age of your arteries. If your vascular age is higher than your chronological age, you may be at higher risk for developing cardiovascular disease.

0.728 mm

Carotid Intima-Media Thickness Test (C-IMT)

The C-IMT is a measurement of the thickness of the innermost two layers of the wall of your carotid artery. An increased thickness indicates the presence of an atherosclerotic disease process and vascular inflammation.


2.57 mm

Largest Plaque


Heterogenous

Plaques can be soft (highest risk), heterogeneous (moderate risk) or calcified (lower risk).

Artery Blockage




Carotid Intima-Media Thickness Test (C-IMT)



Diseases Associated with Obesity






InBody

[InBody770]

		<u>- 7</u>						[InB	ody 770
ID Jane Doe		Hei	ght : 05.0 in	Age 1 31			Test Date 05.28.20		:13
Body Comp	ositi	on An	alysis						
		Valu	ies	Total Bo	dy Water	r Lean B	ody Mass	We	ight
Intracellular Water	(lb)	39.	9	64	2				
Extracellular Wate	r (lb)	24.	3	01	.2	88	3.0	13	5.3
Dry Lean Mass	(lb)	23.	8					10	0.0
Body Fat Mass	(lb)	47.	4						
Muscle-Fat	Ana	lysis							
Weight	(lb)	53	ல் க்	100	135.3	30 145	160 1	75 190	205
SMM Skeletal Muscle Mass	(lb)	1.0	sio 90 4	7.6	110 1	20 130	140 1	50 160	170 %
Body Fat Mass	(lb)	40	ல் வ	100	160 2	47.4	340 4	00 460	520 %
Obesity Ana	lvsi	s							
cong . min	J	_							
BMI Body Mass Index (8	kg/m²)		5.0 18.5	21.0	25.0 3 22.5	0.0 35.0	40.0 45	5.0 50.0	55.0
PBF Percent Body Fut	(%)	8.0 1	5.0 18.0	23.0		35.		53.0	58.0
Segmental I	ean	Angly	eie						
Jeginentai I	Jean	Zinaly	313				A		ECWITEM
Right Arm	(lb) (%)	40	60 80	4.17 - 88.6	120 1	40 160	180 2	00	0.374
Left Arm	(lb) (%)		60 80	4.03 85.6	120 1	40 160	180 2	00	0.374
Trunk	(lb) (%)	70	80 90	= 39.6 92.7	110 1	20 130	140 1	50	0.377
Right Leg	(lb) (%)	70	80 90	13.36 9.6	110 1	20 130	140 1:	50	0.374
Left Leg	(lb) (%)			13.49 90.5	110 t	20 130	140 1	50	0.377
ECW/TBW		lveis		- 4,2					
LC WILDW	. 3112	11,515							
ECW/TBW		0.320 0.	340 0.360		0.390 0. 876	600 0.410	0.420 0.4	0.440	0.450
Body Comp	ositi	on His	torv						
Weight	(lb)	135.5	134.9	135.4	136.1	137.6	135.2	134.6	135.3
SMM Skeletal Muscle Mass	(lb)	42.8	43.2	44.0	44.7	45.6	45.3	45.7	47.6
PBF Percent Body Fat	(%)	40.3	39.5	38.6	37.9	37.4	36.7	35.9	35.0
ECW/TBW		0.376	0.378	0.376	0.374	0.376	0.376	0.378	0.376
✓ Recent □ To	stal	03.12.20 07:13	03.25.20 07:15	04.02.20 07:05	04.16.2 07:01	-	05.02.20 06:45	05.13.20 07:11	05.28.20
_ recent = 10		07:13	07:15	07:05	07:01	06:58	06:45	07:11	07:13

SEE WHAT YOU'RE MADE OF



Body Fat - Lean Body Mass Control Body Fat Mass - 18.3 lb Lean Body Mass + 9.3 lb (+) means to gain fat/lean (-) means to lose fat/lean

Segmental Fat Analysis — **V** | - | **A** Right Arm (3.3 lb) 156.0% Left Arm (3.3 lb) ------158.9% Trunk (24.0 lb) → 202.2% Right Leg (7.3 lb) 132.8% Left Leg (7.1 lb) 132.4%

Basal Metabolic Rate 1231 kcal Leg Lean Mass

26.9 в

TBW/LBM -73.0 % Reactance —

RA LA TR RL LL Xc(Ω) 5 kHz | 21.1 20.9 1.9 20.8 20.2 50 kHz 37.0 36.9 3.2 37.5 35.3 250kHz 32.3 32.2 3.4 26.4 27.8

Whole Body Phase Angle 5.4°

RA LA TR RL LL Ø(°) 50 kHz | 4.7 4.5 7.0 6.2 6.0


Results Interpretation QR Code
Scan the QR Code to see results interpretation in more detail.




Impedance

	RA	LA	TR	RL	LL
$\mathbf{Z}(\Omega) = 1_{\mathbf{kHz}}$					
5 kHz	503.3	521.9	30.0	397.3	386.8
50 kHz	452.0	470.2	26.3	346.4	338.7
250 kHz	411.5	429.7	22.4	313.2	307.3
500 kHz	396.7	414.8	20.0	305.0	300.2
1000 kHz	384.3	402.2	17.8	299.4	294.0


Vulnerable plaque





Erling Falk et al. J Am Coll Cardiol 2006; 47:C7-C12.







Not All Plaque Is the Same. Cleerly.

It's not just about identifying the presence of plaque. Determining the amount and type of atherosclerosis

(plaque) present enables earliest diagnosis and precision treatment possible.




PLAQUES THAT LOOK DIFFERENT BEHAVE DIFFERENTLY.




LOW-DENSITY-NON-CALCIFIED PLAQUE (RED)




NON-CALCIFIED PLAQUE (YELLOW)



ALL PLAQUE TYPES



NON-CALCIFIED (YELLOW) AND CALCIFIED PLAQUE (BLUE)



CAI CIFIFD PLAQUE (BLUE)

HIGH RISK

INTERMEDIATE RISK


LOW RISK

Transforming plaque type is the only trackable approach to personalizing heart attack prevention.

Comparison Report

	Compared		Current
ALL mm³ PAV	Cleerly ID: 7616EE30 10/28/2021	# %	Cleerly ID: C05F9BA1 1/24/2024
Total Plaque Volume (mm³)	269.7	+12%	301.3
▶ Total Non-Calcified Plaque Volume (mm³)	105.7	-17%	87.9
Low-Density - Non-Calcified Plaque Volume (mm³)	1	-100%	0
Total Calcified Plaque Volume (mm³)	164	+30%	213.4

CAUTION: Changes in the patient, scanner, and other technical factors between multiple CT scans may impact the accuracy of the comparison reports. Only segments dRCA, R-PDA, R-PLB, LM, pLAD, dLAD, D1, pCx, LCx, and OM1 were considered, any remaining were excluded from the comparison analysis because of significant differences in image quality, artifacts, stents, or presence of occlusions, therefore the plaque volumes here only represent plaque from comparable segments and may be less than plaque volumes reported elsewhere.



Regular Exercise
Healthy Diet
Connection with others
Stress Management

Continuous Glucose Monitoring


Different people spike to different foods

Dexcom








Abbott



Glucotypes









Am J Clin Nutr. 2004 Apr;79(4):682-90. doi: 10.1093/ajcn/79.4.682. Increase in intranuclear nuclear factor kappaB and decrease in inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect

Patients were given an egg-muffin and sausage-muffin and 2 hash browns, which contained 910kcal, 81g carbohydrate, 51g fat, and 32 g protein over 15

min.







Triglycerides - proxy for insulin resistance - carb reduction

Saturated Fats raise Apo B Worst are tropical oils (Coconut or Palm - C18)


Saturated Fats also inhibit the sterol Binding protein in the liver resulting in fewer LDLR



LYON DIET-HEART STUDY



© The Noskes Foundation, Cape Town - 2015.



Adv Nutr. 2021 Mar; 12(2): 363-373. Published online 2020 Oct 1.

doi: 10.1093/advances/nmaa116

PMCID: PMC8009747PMID: 33002104


The Mediterranean Dietary Pattern and Inflammation in Older

Adults: A Systematic Review and Meta-analysis


Study name			Stati	stics for e	ach study					SMD	and 959	% CI	
		Standard						Relative					
	SMD	error	Variance	95%	6 CI	Z-value	P-value	weight					
Chan et al. (23) Men	-0.093	0.080	0.006	-0.249	0.064	-1.161	0.246	18.16	- 1	- 1 -	=	- 1	- 1
Chan et al. (23) Women	-0.043	0.079	0.006	-0.198	0.113	-0.540	0.589	18.20	- 1			- 1	- 1
Gu et al. (41)	-0.224	0.075	0.006	-0.371	-0.076	-2.969	0.003	18.54	-	━┼─¯	- I	- 1	- 1
Lo Buglio et al. (24)	-0.656	0.199	0.040	-1.046	-0.266	-3.298	0.001	9.08	- 1	<u></u>	- I	- 1	- 1
Shahar et al. (43)	-0.290	0.101	0.010	-0.487	-0.092	-0.879	0.004	16.31	- 1		_	- 1	- 1
Waldeyer et al. (44)	-0.430	0.061	0.004	-0.549	-0.310	-7.022	0.000	19.71					
Overall effect	-0.258	0.076	0.006	-0.410	-0.105	-3.316	0.001		-1.00	-0.50	0.00	0.50	1.0
									Decre	eased CRP		Increased	CRP



Mediterranean Diet and Cancer




Mediterranean diet and cognitive function




Mediterranean diet and Chronic Diseases

	Relative	¥:			
Outcome	Risk (95% CI)	NStudies	NMedDiet	NControl	Reference
Overall mortality	1.00 (0.86, 1.16)	5	6630	4041	Liyanage 2016
CVD mortality	0.59 (0.39, 0.90)	4	7418	4875	Grosso 2015
CHD incidence	0.48 (0.33, 0.70)	1	499	501	Becerra-Tomas 2019
Stroke incidence ———	0.64 (0.47, 0.87)	2	6617	4071	Grosso 2015
Myocardial infarction incidence	0.66 (0.48, 0.90)	3	7116	4572	Grosso 2015
Composite CVD ———	0.55 (0.39, 0.77)	4	7418	4875	Grosso 2015
Type 2 diabetes -	0.70 (0.54, 0.91)	1	2394	1147	Salas-Salvado 2014
Metabolic Syndrome ———	0.45 (0.32, 0.64)	2	902	482	Kastorini 2017
Breast cancer	0.41 (0.19, 0.88)	1	2761	1391	Toledo 2015




jure 2. Quantitative coronary angiograms and cardiac PET scape obtained

Mean Changes in Telomere Length After 5 Years



Ornish D et al. *Lancet Oncol.* 2013;14(11):1112-20.



Omega-3 fatty acids

Low levels of EPA and DHA (Omega-3 Index) are associated with early-onset coronary atherosclerosis.

	RISK								
High (<2.2%)	Moderate (2.2%-3.2%)	Low (>3.2%)	The Omega-3 Index is associated with a low risk of cardiovascular disease because it is in the top population						
		~	quartile. The Omega-3 Index categories are based on the top (75th percentile) and bottom (25th percentile) quartiles of the reference population. Consumption of foods high in omega-3 fatty acids (EPA and DHA) or supplements containing omega-3 fatty acids can increase the Omega-3 Index. Index <2.2: High Index 2.2-3.2: Moderate Index >3.2: Optimal						


Test Name	In Range	Out of Range	Reference Range/Comments					
OMEGA 3 AND 6 FATTY ACIDS, PLASMA								
			1.4-4.9 %					
OMEGA 3 (EPA+DHA) INDEX		6.7 H	See Note 1					
OMEGA 6/OMEGA 3 RATIO		3.4 L	5.7-21.3					
EPA/ARACHIDONIC ACID RATIO		0.3 H	0.2 OR LESS					
ARACHIDONIC ACID	10.9		5.2-12.9 %					
EPA		3.3 H	0.2-1.5 %					
			1.2-3.9 %					
DHA	3.4		See Note 2					

	Foods High in Omega-3*								
Fish	Oils	Nuts and Seeds	Grains and Beans						
Salmon	Walnut	Walnuts	Soybeans						
Mackerel	Soybean	Flax seeds	Tofu						
Sardines	Flax	Pecans							
Swordfish	Canola								
Bluefish	Cod liver								
Crab	Olive								
Cod	Sardine								
Scallops									


^{*} Adapted from http://www.tufts.edu/med/nutrition-infection/hiv/health omega3.html, March 13, 2012

Bittner, D.O., Goeller, M., Zopf, Y. *et al.* Early-onset coronary atherosclerosis in patients with low levels of omega-3 fatty acids. *Eur J Clin Nutr* 74, 651–656 (2020). https://doi.org/10.1038/s41430-019-0551-5

The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance




Liao J, Xiong Q, Yin Y, Ling Z, Chen S. The Effects of Fish Oil on Cardiovascular Diseases: Systematical Evaluation and Recent Advance. Front Cardiovasc Med. 2022 Jan 5;8:802306. doi: 10.3389/fcvm.2021.802306. PMID: 35071366; PMCID: PMC8767101.



Effect of Omega-3 Fatty Acids on Telomeres—Are They the Elixir of Youth?

Omega-3

supplementation



Anti inflammatory markers formation:

- Prostaglandins 3 series
- Thromboxanes A3
- Leucotriens B5
- Resolvins
- Maresins
- Lipoxins
- · IL6r
- · IL10
- TGFbeta

Reduced proinflammatory markers:

- IL6
- CRP
- IL1
- TNF

Antioxidant effect:

- · Reduced NO formation
- ROS scavenging
- Reduced SSBs
- Shelterin protection

Direct action on:

- Telomerase active site
- Telomerase transcription
- · TERT epigenetic regulation
- Cell proliferation



Reduced Telomere atrition

Reduced Oxidative Stress and lipid


peroxidation


Ogłuszka M, Lipiński P, Starzyński RR. Effect of Omega-3 Fatty Acids on Telomeres-Are They the Elixir of Youth? Nutrients. 2022 Sep 9;14(18):3723. doi: 10.3390/nu14183723. PMID: 36145097; PMCID: PMC9504755

Sleep Duration and All-Cause Mortality: A Systematic Review and Meta-Analysis of Prospective Studies Sleep. 2010 May 1; 33(5): 585–592.

 Both short (≤6 hours/day) and long (≥8 hours/day) sleep durations increase the risk of mortality compared with sleep of 7 hours/day

Simple 7 (8): **Smoking Healthy Diet** Weight Cholesterol **Blood Pressure Blood Glucose Physical Activity** (Sleep)





glucagon-like peptide-1 receptor agonist

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

N Engl J Med 2023; 389:2221-2232

CONCLUSIONS

• In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months.



Berberine

Berberine is a plant alkaloid derived from roots, rhizomes, and stem bark of several plants with a historical use in various ancient medicines.

From: Advances in Molecular Toxicology, 2017

Berberine

BBR has been recognized as being capable of decreasing cardiovascular risk through reducing oxidative stress, low-density lipoprotein (LDL), triglycerides, and insulin resistance and improving the mood. 22 A multicenter randomized trial showed BBR reduced LDL-c levels as well as total cholesterol/HDL-c and ApoB/ApoA1 ratios, while increasing Apo A1, all of which are improvements in cardiovascular risk indicators. 23

Berberine is possibly

effective for...



- Canker sores. Applying a gel containing berberine can reduce pain, redness, oozing, and the size of canker sores.
- **Diabetes**. Taking berberine by mouth seems to slightly reduce blood sugar levels in people with diabetes.
- A digestive tract infection that can lead to ulcers (Helicobacter pylori or H. pylori). Adding berberine by mouth to multiple medications that are typically used to treat this condition might work as well as other accepted treatments for this condition. These other treatments also use multiple medications.
- High levels of cholesterol or other fats (lipids) in the blood (hyperlipidemia).
 Taking berberine by mouth, alone or with other ingredients, might help lower total cholesterol, low-density lipoprotein (LDL or "bad") cholesterol, and triglyceride levels in people with high cholesterol.
- High blood pressure. Taking 0.9 grams of berberine by mouth daily along with the blood pressure-lowering drug amlodipine reduces blood pressure better than taking amlodipine alone in people with high blood pressure.
- A hormonal disorder that causes enlarged ovaries with cysts (polycystic ovary syndrome or PCOS). Taking berberine by mouth might lower blood sugar, improve cholesterol and triglyceride levels, reduce testosterone levels, and lower waist-to-hip ratio in people with PCOS.

Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants
Front Cardiovasc Med. 2022; 9: 964977. Published online 2022 Aug 22.

Nattokinase (NK), known as a potent fibrinolytic and antithrombotic agent, has been shown to have antiatherosclerotic and lipid-lowering effects.


A significant reduction in the thickness of the carotid artery intima-media and the size of the carotid plaque was observed.

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
List of authors.

The AIM-HIGH Investigators


There was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels.

Sirolimus (Rapamycin) is the product of the bacterium Streptomyces hygroscopicus originally found in a soil sample from Easter Island, also known as "Rapa Nui." Because of this history, sirolimus has been marketed as rapamycin and has been found to be an effective immunosuppressant as well as antiproliferative agent.



Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure
Effect of mTOR inhibition with rapamycin on pathologic remodeling in established HF PLoS One. 2013; 8(12)


Front Cardiovasc Med. 2021; 8: 753664.




Photobiomodulation therapy is defined as the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures that are receptive to photons.

Mitochondria is particularly receptive to red and near-infrared (NIR) photons. At the cellular level, visible red and near infrared light energy are absorbed by mitochondria, which perform the function of producing ATP

The key to this entire process is a mitochondrial enzyme called cytochrome oxidase c, a chromophore, which accepts photonic energy of specific wavelengths when functioning below par.









Reduced
CRP
LDL
Tgd
Markers of
Plaque
Instability

Whole-Body Cryotherapy Decreases the Levels of Inflammatory, Oxidative Stress, and Atherosclerosis Plaque
Mediators Inflamm. 2018; 2018: 8592532.





Intermittent Fasting
N Engl J Med 2019; 381:2541-2551

Amazoning Health Care

You do your shopping at home – why would you not do your healthcare at home?





Wearables




Microsampling









Coraeon.com Functionalheart.com Lifesciencepharmacy.com

Giovanni Campanile, MD, FACC Scott Berliner R.Ph.





PHARMACY

Questions?

Hormones and Cardiovascular Health

Hormones may influence many pathways in the cardiovascular system, which includes the heart and blood vessels. While hormones play a key role in maintaining cardiovascular health, high levels of some hormones can contribute to cardiovascular disease.





Pamela Ouyang, Erin D. Michos, Richard H. Karas, Hormone Replacement Therapy and the Cardiovascular System: Lessons Learned and Unanswered Questions, Journal of the American College of Cardiology, Volume 47, Issue 9, 2006, Pages 1741-1753, ISSN 0735-1097,

https://doi.org/10.1016/j.jacc.2005.10.076.


Do hormones play a role in women's heart health?

Estrogen is protective of the heart in the pre-menopausal years—it relaxes the arteries and promotes good cholesterol. "But as menopause approaches, estrogen declines, and we see more cardiovascular risk factors, such as high cholesterol and hypertension, in women," Dr. Spatz says. "The incidence of heart disease in women starts going up around age 65—about 10 years later than in men—and that's likely due to the lingering positive effects of estrogen."

When prescribed properly, estrogen is considered mostly safe and may help lower cardiovascular risk, but only in women younger than 60 or who are less than 10 years into menopause and do not have heart disease.

The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?

Miller VM, Naftolin F, Asthana S, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Gleason CE, Hodis HN, Jayachandran M, Kantarci K, Lobo RA, Manson JE, Pal L, Santoro NF, Taylor HS, Harman SM. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019 Sep;26(9):1071-1084. doi: 10.1097/GME.000000000001326. PMID: 31453973; PMCID: PMC6738629.



Integrated Effects of Menopausal Hormonal Treatments - KEEPS

Brain

Both o-CEE & tE2:

- Neutral effect on cognition
- ↓ Hot flashes
- Improved sleep

CEE only:

Anxiety & depression

tE2 only:

- ↓ Deposition β-amyloid
- ↑ Libido

Both o-CEE & tE2:

Neutral effect on CIMT

 No significant differences in coronary artery calcification

 Maintained bone mineral density




Both o-CEE & tE2:

- ↓ HOMA-IR
- CEE only:
- ↑ HDL: LDL



In general, KEEPS data provide reassurance regarding the efficacy and safety of these specific doses of oCEE (0.45 mg/day) or tE2 (50 µg/day), both with oral progesterone (200 mg/day for 12 days/month), for women who may be considering use of MHT to reduce postmenopausal symptoms. As with any randomized clinical trial, the results may not be generalizable to patients outside the study population, such as older women or those at higher cardiovascular risk.

"The protective role of estrogen in cardiovascular diseases is associated with a decrease in fibrosis, stimulation of angiogenesis and vasodilation, enhancement of mitochondrial function and reduction in oxidative stress"




Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women's cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2022 Dec 10;19(2):458-466. doi: 10.5114/aoms/157308. PMID: 37034540 PMCID: PMC10074318.

Menopause is now listed as a female-specific CVD risk factor per the American Heart Association

By following women over the MT, SWAN documented sharp increases in total cholesterol, low-density lipoprotein cholesterol (LDL-C) and apolipoprotein (Apo)B levels within a 1-year interval surrounding the FMP (final menses period). 72 Importantly, the menopause-related acceleration in LDL-C was associated with greater risk of carotid plaque later in life in a follow-up analysis.

Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis



These results provided evidence that early age at menopause is associated with a modestly greater risk of HF. Identification of women with early menopause offers a window of opportunity to implement interventions that will improve overall cardiovascular health during the postmenopausal years.


Appiah D, Schreiner PJ, Demerath EW, Loehr LR, Chang PP, Folsom AR. Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis. J Am Heart Assoc. 2016 Jul 28;5(8):e003769. doi: 10.1161/JAHA.116.003769. PMID: 27468929; PMCID: PMC5015298.

What about men?

Role of androgens in cardiovascular pathology

Androgenic steroid hormones act through genomic and non-genomic mechanisms and significantly influence the function of ECs (Endothelial cells) and their progenitors. These hormones are involved in the regulation of the vascular tone, proliferation, mobility, adhesion, and anti-thrombotic properties of vascular endothelium. Androgens also participate in important pathogenic mechanisms such as atherogenesis and vascular inflammation. Many studies indicate that androgens play a vasculoprotective role through the anti-inflammatory, anti-apoptotic, and vasodilatory actions on endothelium and VSMCs (vascular smooth muscle cells) and recruitment of epithelial progenitor cells, EPCs essential for vascular repair.

In the context of human disease relevance, androgen deficiency treated with testosterone prescriptions at physiological concentrations has been associated with lower cardiometabolic risk and treatment outcomes.




The prevalence of cardiovascular mortality is higher in men than in agematched premenopausal women. Gender differences are linked to circulating sex-related steroid hormone levels and their cardio-specific actions, which are critical factors involved in the prevalence and features of age-associated cardiovascular disease.

In women, estrogens have been described as cardioprotective agents, while in men, testosterone is the main sex steroid hormone. The effects of testosterone as a metabolic regulator and cardioprotective agent in aging men are poorly understood. With advancing age, testosterone levels gradually decrease in men, an effect associated with increasing fat mass, decrease in lean body mass, dyslipidemia, insulin resistance and adjustment in energy substrate metabolism.

Thyroid Health

- Approximately one-fourth of overtly hypothyroid patients have reversible, predominantly diastolic, hypertension. Indeed, blood pressure and TSH levels have been correlated, even within the reference range
- Increases in plasma homocysteine levels have been reported in overt hypothyroidism and, in some studies, with subclinical hypothyroidism
- In some studies, subclinical hypothyroidism has also been associated with other risk factors for ASCVD, including a hypercoagulable state, increased carotid intima-media thickness, decreased flow-mediated vasodilation and nitric oxide availability, and higher high-sensitivity C-reactive proteins levels

(We measure all of these markers in our patients)




Factors that inhibit proper production of thyroid hormones

- Stress
- Infection, trauma, radiation, medications
- Fluoride (antagonist to iodine)
- Toxins: pesticides, mercury, cadmium, lead
- Autoimmune disease: Celiac

Factors that increase conversion of T4 to RT3

- Stress
- Trauma
- Low-calorie diet
- Inflammation (cytokines, etc.)
- Toxins
- Infections
- Liver/kidney dysfunction
- Certain medications




New-Onset Heart Failure in the Setting of T4-Conversion Disorder

Providers should be mindful of patients who may have T4-conversion disorder, as low T3 is a strong prognostic predictor of death in patients with heart disease. Further research is warranted in discovering the pathophysiology in which T4-conversion disorders manifest. With this, optimal thyroid hormone therapy may be tailored for these individuals and improve their quality of life. By sharing this case, we aim to aid providers with their differential diagnoses and bring to light a potential area of further investigation.

My Approach:

- Being clinical about finding the appropriate supplements
- Listen to symptoms and matching it with lab levels, not looking at them as independent concerns
- Monitor nutrient levels and editing supplements as appropriate
- Monitor Thyroid Health
- Monitor Hormone Health



"The Sicilian Secret Diet Plan is a must-read for anyone looking to live a happier, healthier, and longer life!" -Jason Wachob, Founder and Co-CEO, mindbodygreen THE SICILIAN SECRET DIET PLAN CENTURIES OF GOOD HEALTH FROM THE CENTER OF THE MEDITERRANEAN GIOVANNI CAMPANILE, M.D. FUNCTIONAL CARDIOLOGIST AND CO-FOUNDER OF CORAEON ANTI-AGING PRACTICE IN NYO AND SANDRA CAMMARATA, M.D.


functionalheart.com

PSYCHIATRIST AND CHEF



PHARMACY

www.lifesciencepharmacy.com



Coraeon.com Functionalheart.com Giovanni Campanile, MD, FACC Scott Berliner R.Ph.



Friday 1:30pm – 2:30pm

The Heart of Anti-Aging

Please scan this QR code on you mobile or tablet device to access the session feedback survey



The Heart of Anti-Aging